Benign prostatic hyperplasia (BPH), which causes lower urinary tract symptoms (LUTS), is a common diagnosis among the ageing male population with increasing prevalence. Many risks factors, both modifiable and non-modifiable, can increase the risk of development and progression of BPH and LUTS. The symptoms can be obstructive (resulting in urinary hesitancy, weak stream, straining or prolonged voiding) or irritative (resulting in increased urinary frequency and urgency, nocturia, urge incontinence and reduced voiding volumes), or can affect the patient after micturition (for example, postvoid dribble or incomplete emptying). BPH occurs when both stromal and epithelial cells of the prostate in the transitional zone proliferate by processes that are thought to be influenced by inflammation and sex hormones, causing prostate enlargement. Patients with LUTS undergo several key diagnostic investigations before being diagnosed with BPH. Treatment options for men with BPH start at watchful waiting and progress through medical to surgical interventions. For the majority of patients, the starting point on the treatment pathway will be dictated by their symptoms and degree of bother.
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Lepor, H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev. Urol. 7, S3–S12 (2005).
Roehrborn, C. G. Pathology of benign prostatic hyperplasia. Int. J. Impot. Res. 20, S11–S18 (2008).
Young, J. M., Muscatello, D. J. & Ward, J. E. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int. 85, 1037–1048 (2000).
Parsons, J. K. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr. Bladder Dysfunct. Rep. 5, 212–218 (2010).
Berry, S. J., Coffey, D. S., Walsh, P. C. & Ewing, L. L. The development of human benign prostatic hyperplasia with age. J. Urol. 132, 474–479 (1984).
Platz, E. et al. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of united states men. J. Urol. 188, 496–501 (2012). This study followed up ∼26,000 men with LUTS for 16 years and reported that the incidence and progression rates are high and increase steeply as men age.
Bosch, J. L., Hop, W. C., Kirkels, W. J. & Schroder, F. H. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 46, 34–40 (1995).
Barry, M. J. et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med. Care 33, AS145–AS155 (1995).
Rohrmann, S., Smit, E., Giovannucci, E. & Platz, E. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int. J. Obes. 29, 310–316 (2005). This study involved 2,372 men >60 years of age and demonstrated that diabetes and hypertension seem to be positively associated with the development of LUTS.
Jin, B., Turner, L., Zhou, Z., Zhou, E. & Handelsman, D. Ethnicity and migration as determinants of human prostate size. J. Clin. Endocrinol. Metab. 84, 3613–3619 (1999). This study focused on the roles of ethnicity and migration on prostate size, demonstrating that prostate size in middle life is subject to environmental factors that are related to migration.
Loeb, S. et al. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J. Urol. 182, 1458–1462 (2009).
Roehrborn, C. G. et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int. 107, 946–954 (2011).
De Nunzio, C., Aronson, W., Freedland, S., Giovannucci, E. & Parsons, J. The correlation between metabolic syndrome and prostatic diseases. Eur. Urol. 61, 560–570 (2012).
Hammarsten, J., Hogstedt, B., Holthuis, N. & Mellstrom, D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1, 157–162 (1998).
Gacci, M. et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 115, 24–31 (2015). This review summarizes the literature on the relationship between metabolic syndrome and BPH and concluded that obese, dyslipidaemic and aged men have a higher risk of having metabolic syndrome as a determinant of their prostate enlargement.
Golbidi, S. & Laher, I. Bladder dysfunction in diabetes mellitus. Front. Pharmacol. 1, 136 (2010).
Yoshimura, N., Chancellor, M. B., Andersson, K. E. & Christ, G. J. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int. 95, 733–738 (2005).
Michel, M. C., Chess-Williams, R. & Hegde, S. S. Are blood vessels a target to treat lower urinary tract dysfunction? Naunyn Schmiedebergs Arch. Pharmacol. 388, 687–694 (2015).
Abdollah, F. et al. Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J. Urol. 52, 507–516 (2011).
Vignozzi, L. et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J. Endocrinol. 212, 71–84 (2012). This experimental animal study reported the protective effect of testosterone on metabolic syndrome-induced prostatic hypoxia, fibrosis and inflammation, which can play a part in the development of BPH and LUTS.
Vignozzi, L. et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 73, 789–800 (2013). This study examined BPH specimens from men and reported that fats and insulin might be a factor in the development of BPH as they boost inflammation; DHT might counteract these actions and benefit prostate health.
Kellogg Parsons, J., Sarma, A., McVary, K. & Wei, J. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J. Urol. 189, S102–S106 (2013). This review showed that obesity markedly increases the risk of BPH, but this risk can be reduced by physical activity.
Patel, N. & Parsons, J. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J. Urol. 30, 170–176 (2014).
Kristal, A. et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention trial. J. Urol. 177, 1395–1400 (2007).
Parsons, J. et al. Metabolic factors associated with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 91, 2562–2568 (2006).
Furukawa, S. et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752–1761 (2004).
Rohrmann, S., De Marzo, A., Smit, E., Giovannucci, E. & Platz, E. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 62, 27–33 (2005).
Lagiou, P. et al. Diet and benign prostatic hyperplasia: a study in Greece. Urology 54, 284–290 (1999). This case–control study compared patients with confirmed BPH to a control group to assess the role of diet in the disease. The authors concluded that lipids, butter and margarine increase the risk of BPH, whereas fruit intake reduces the risk.
Bravi, F. et al. Food groups and risk of benign prostatic hyperplasia. Urology 67, 73–79 (2006).
Denis, L., Morton, M. & Griffiths, K. Diet and its preventive role in prostatic disease. Eur. Urol. 35, 377–387 (1999).
Qi, J. et al. Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population. Prostate 73, 1182–1190 (2013).
Jiao, Y. et al. LILRA3 is associated with benign prostatic hyperplasia risk in a Chinese population. Int. J. Mol. Sci. 14, 8832–8840 (2013).
Sanda, M. G., Beaty, T. H., Stutzman, R. E., Childs, B. & Walsh, P. C. Genetic susceptibility of benign prostatic hyperplasia. J. Urol. 152, 115–119 (1994). This study assessed the genetic susceptibility in men undergoing prostatectomy for BPH and reported that the first-degree relatives of men from this group had a fourfold increased risk of developing BPH that required surgery compared with the relatives of control men.
Pearson, J. D. et al. Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology 61, 781–785 (2003). This study reported that the mode of inheritance for BPH has been suggested to be autosomal dominant for certain men.
Meikle, A., Bansal, A., Murray, D., Stephenson, R. & Middleton, R. Heritability of the symptoms of benign prostatic hyperplasia and the roles of age and zonal prostate volumes in twins. Urology 53, 701–706 (1999).
Rohrmann, S. et al. Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins. Epidemiology 17, 419–427 (2006). In this study, the concordance rates for LUTS in 1,723 twin pairs were higher in monozygotic than in dizygotic twins and suggested that 72% of the risk of high-to-moderate and severe LUTS was attributable to genetic factors.
Foster, C. S. Pathology of benign prostatic hyperplasia. Prostate Suppl. 9, 4–14 (2000).
Griffiths, K., Morton, M. S. & Nicholson, R. I. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Eur. Urol. 32 (Suppl. 3), 24–40 (1997).
Carson, C. 3rd & Rittmaster, R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61, 2–7 (2003). Growth factors stimulated by DHT, including EGF, KGF and IGFs, modulate cellular proliferation in the prostate in humans.
Isaacs, J. T. Antagonistic effect of androgen on prostatic cell death. Prostate 5, 545–557 (1984).
Niu, Y. et al. Proliferation and differentiation of prostatic stromal cells. BJU Int. 87, 386–393 (2001).
Kim, I. Y. et al. Modulation of sensitivity to transforming growth factor-β1 (TGF-β1) and the level of type II TGF-β receptor in LNCaP cells by dihydrotestosterone. Exp. Cell Res. 222, 103–110 (1996).
Chughtai, B., Lee, R., Te, A. & Kaplan, S. Inflammation and benign prostatic hyperplasia: clinical implications. Curr. Urol. Rep. 12, 274–277 (2011).
Theyer, G. et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab. Invest. 66, 96–107 (1992).
Kramer, G., Mitteregger, D. & Marberger, M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur. Urol. 51, 1202–1216 (2007).
Kramer, G. et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 52, 43–58 (2002).
Steiner, G. E. et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab. Invest. 83, 1131–1146 (2003).
Robert, G. et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69, 1774–1780 (2009). This study examined prostate tissue from men who underwent surgery for BPH and reported that patients with high-grade inflammation had a significantly higher IPSS, as well as larger prostate volumes, than those with low-grade inflammation.
Wang, W., Bergh, A. & Damber, J. E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61, 60–72 (2004).
Shapiro, E., Becich, M. J., Hartanto, V. & Lepor, H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J. Urol. 147, 1293–1297 (1992).
Roehrborn, C. G. & Schwinn, D. A. α1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J. Urol. 171, 1029–1035 (2004).
Lepor, H., Tang, R. & Shapiro, E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 22, 301–307 (1993).
Kobayashi, S., Tang, R., Shapiro, E. & Lepor, H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J. Urol. 150, 2002–2006 (1993).
Andersson, K.-E. α-Adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α-adrenoceptor antagonists. World J. Urol. 19, 390–396 (2002).
Yamada, S. et al. Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy. J. Pharmacol. Exp. Ther. 242, 326–330 (1987).
Siroky, M. B. The aging bladder. Rev. Urol. 6, S3–S7 (2004).
Fowler, C. J. Neurological disorders of micturition and their treatment. Brain 122, 1213–1231 (1999).
Abrams, P. H., Farrar, D. J., Turner-Warwick, R. T., Whiteside, C. G. & Feneley, R. C. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J. Urol. 121, 640–642 (1979). In this study, despite surgical intervention for obstruction due to BPH, approximately one-third of men continued to have symptoms of voiding dysfunction, including both detrusor overactivity and decreased detrusor compliance.
Barry, M. J. et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J. Urol. 150, 351–358 (1993).
Gosling, J. A. & Dixon, J. S. Structure of trabeculated detrusor smooth muscle in cases of prostatic hypertrophy. Urol. Intern. 35, 351–355 (1980).
Gosling, J. A., Gilpin, S. A., Dixon, J. S. & Gilpin, C. J. Decrease in the autonomic innervation of human detrusor muscle in outflow obstruction. J. Urol. 136, 501–504 (1986).
Levin, R. M., Wein, A. J., Saito, M. & Longhurst, P. A. Factors that modulate the initiation of micturition. Scand. J. Urol. Nephrol. Suppl. 175, 3–10 (1995).
Levin, R. M. et al. Obstructive response of human bladder to BPH versus rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol. Urodynam. 19, 609–629 (2000).
Lin, V. K. & McConnell, J. D. Effects of obstruction on bladder contractile proteins. Prog. Clin. Biol. Res. 386, 263–269 (1994).
Mannikarottu, A. S., Changolkar, A. K., Disanto, M. E., Wein, A. J. & Chacko, S. Over expression of smooth muscle thin filament associated proteins in the bladder wall of diabetics. J. Urol. 174, 360–364 (2005).
Mannikarottu, A. S. et al. Regional alterations in the expression of smooth muscle myosin isoforms in response to partial bladder outlet obstruction. J. Urol. 173, 302–308 (2005).
Cher, M. L., Abernathy, B. B., McConnell, J. D., Zimmern, P. E. & Lin, V. K. Smooth-muscle myosin heavy-chain isoform expression in bladder-outlet obstruction. World J. Urol. 14, 295–300 (1996).
European Association of Urology. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (luts), incl. benign prostatic obstruction (BPO). EAU http://uroweb.org/wp-content/uploads/EAU-Guidelines-Management-of-non-neurogenic-male-LUTS-2016.pdf (2016).
McVary, K. T. et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J. Urol. 185, 1793–1803 (2011).
Gratzke, C. et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 67, 1099–1109 (2015). Together with reference 69, the American and European guidelines highlight the importance of the medical history as the most important assessment tool and recommend the use of the validated IPSS questionnaire to objectively assess male LUTS, as well as routine urinalysis (either dipstick analysis or microscopic evaluation) in the primary evaluation of a patient presenting with LUTS.
Roehrborn, C. G. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 51, 19–22 (1998).
Abrams, P. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodynam. 21, 167–178 (2002).
Yap, T. L., Cromwell, D. C. & Emberton, M. A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. BJU Int. 99, 9–16 (2007).
Bright, E., Drake, M. J. & Abrams, P. Urinary diaries: evidence for the development and validation of diary content, format, and duration. Neurourol. Urodynam. 30, 348–352 (2011).
Cornu, J. N. et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management — a systematic review and meta-analysis. Eur. Urol. 62, 877–890 (2012).
Weiss, J. P. et al. Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol. Urodynam. 31, 330–339 (2012).
American Urological Association. American Urological Association guideline: management of benign prostatic hyperplasia (BPH). AUA https://www.auanet.org/common/pdf/education/clinical-guidance/Benign-Prostatic-Hyperplasia.pdf (2010).
Davis, R. et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J. Urol. 188, 2473–2481 (2012).
Asimakopoulos, A. D. et al. Measurement of post-void residual urine. Neurourol. Urodynam. 35, 55–57 (2016).
Rule, A. D. et al. Longitudinal changes in post-void residual and voided volume among community dwelling men. J. Urol. 174, 1317–1321 (2005).
Sullivan, M. P. & Yalla, S. V. Detrusor contractility and compliance characteristics in adult male patients with obstructive and nonobstructive voiding dysfunction. J. Urol. 155, 1995–2000 (1996).
Oelke, M. et al. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur. Urol. 52, 827–834 (2007).
Roehrborn, C. G. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int. 97, 734–741 (2006).
Jorgensen, J. B., Jensen, K. M. & Mogensen, P. Age-related variation in urinary flow variables and flow curve patterns in elderly males. Br. J. Urol. 69, 265–271 (1992).
Kranse, R. & van Mastrigt, R. Causes for variability in repeated pressure-flow measurements. Urology 61, 930–934; discussion 934–935 (2003).
Reynard, J. M. et al. The ICS-’BPH’ study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br. J. Urol. 82, 619–623 (1998). The authors studied 1,271 men (45–88 years of age) in 12 centres worldwide over a 2-year period and reported that a Qmax of <10 ml per second had a positive predictive value of 70% for BOO.
Bohnen, A. M., Groeneveld, F. P. & Bosch, J. L. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur. Urol. 51, 1645–1652 (2007). This study demonstrated that the level of serum PSA reflects prostate volume; the higher the PSA level, the greater the likelihood of an enlarged prostate.
Roehrborn, C. G., Boyle, P., Gould, A. L. & Waldstreicher, J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53, 581–589 (1999).
Vickers, A., Carlsson, S., Laudone, V. & Lilja, H. It ain’t what you do, it’s the way you do it: five golden rules for transforming prostate-specific antigen screening. Eur. Urol. 66, 188–190 (2014).
Gerber, G. S., Goldfischer, E. R., Karrison, T. G. & Bales, G. T. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 49, 697–702 (1997). Serum creatinine measurements in 246 consecutive men with LUTS due to BPH revealed that 11% of men have renal insufficiency; however, diabetes mellitus or hypertension are the most likely causes of the increased creatinine concentration in this group.
Weinstein, J. R. & Anderson, S. The aging kidney: physiological changes. Adv. Chronic Kidney Dis. 17, 302–307 (2010).
Davies, D. F. & Shock, N. W. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J. Clin. Invest. 29, 496–507 (1950).
Rowe, J. W., Andres, R., Tobin, J. D., Norris, A. H. & Shock, N. W. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J. Gerontol. 31, 155–163 (1976).
Koch, W. F., Ezz el Din, K., de Wildt, M. J., Debruyne, F. M. & de la Rosette, J. J. The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J. Urol. 155, 186–189 (1996).
Mebust, W. K., Holtgrewe, H. L., Cockett, A. T. & Peters, P. C. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J. Urol. 141, 243–247 (1989).
Loch, A. C. et al. Technical and anatomical essentials for transrectal ultrasound of the prostate. World J. Urol. 25, 361–366 (2007).
Stravodimos, K. G. et al. TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up? Int. Urol. Nephrol. 41, 767–771 (2009).
Chia, S. J., Heng, C. T., Chan, S. P. & Foo, K. T. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int. 91, 371–374 (2003).
Jeong, S. J. et al. Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. Korean J. Urol. 53, 342–348 (2012).
Thomas, A. W., Cannon, A., Bartlett, E., Ellis-Jones, J. & Abrams, P. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int. 93, 745–750 (2004).
Stohrer, M. et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur. Urol. 56, 81–88 (2009).
Verhamme, K. M., Sturkenboom, M. C., Stricker, B. H. & Bosch, R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 31, 373–388 (2008).
Djavan, B. et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. 64, 1144–1148 (2004). This longitudinal study over a period of 4 years, involving almost 400 men, demonstrated that the cumulative clinical progression rate was 6%, 13%, 15%, 24%, 28% and 31% at 6, 12, 18, 24, 36 and 48 months, respectively; 4.9% of patients developed acute urinary retention.
Lepor, H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev. Urol. 9, 181–190 (2007). The pathophysiology of BOO in men with BPH has been attributed to both static (prostatic tissue) and dynamic (smooth muscle) factors, with the α1A-adrenoceptor being the predominate receptor in prostate stromal smooth muscle.
Foglar, R., Shibata, K., Horie, K., Hirasawa, A. & Tsujimoto, G. Use of recombinant alpha 1- adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur. J. Pharmacol. 288, 201–207 (1995).
Montorsi, F. Profile of silodosin. Eur. Urol. Supplements 9, 491–495 (2010).
Marks, L. S., Gittelman, M. C., Hill, L. A., Volinn, W. & Hoel, G. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 Phase 3 studies. J. Urol. 181, 2634–2640 (2009).
Yamanishi, T. et al. Urodynamic effects of silodosin, a new α1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol. Urodynam. 29, 558–562 (2010).
Michel, M. C. α1-Adrenoceptors and ejaculatory function. Br. J. Pharmacol. 152, 289–290 (2007).
Giuliano, F. et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur. Urol. 63, 506–516 (2013).
Oelke, M. et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur. Urol. 61, 917–925 (2012). PDE5 inhibition possibly increases tissue perfusion, modulates autonomic nervous system activity and inhibits the prostatic inflammatory process, all of which lead to improvements in voiding symptoms.
Porst, H. et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur. Urol. 56, 727–735 (2009).
Gacci, M. et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur. Urol. 61, 994–1003 (2012).
Regadas, R. P. et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. Int. Urol. Nephrol. 45, 39–43 (2013).
Wang, P., Luthin, G. R. & Ruggieri, M. R. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J. Pharmacol. Exp. Ther. 273, 959–966 (1995).
Hegde, S. S. & Eglen, R. M. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. 64, 419–428 (1999).
Abrams, P. et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br. J. Pharmacol. 148, 565–578 (2006).
Robinson, D. & Cardozo, L. Solifenacin in the management of the overactive bladder syndrome. Int. J. Clin. Pract. 59, 1229–1236 (2005).
Thiagamoorthy, G., Kotes, S., Zacchè, M. & Cardozo, L. The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder. Ther. Adv. Urol. 8, 38–46 (2016).
Roehrborn, C. G. et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 57, 123–131 (2010). The combination of dutasteride and tamsulosin has been shown to not only produce durable improvements in voiding symptoms but also results in a significant reduction in the risk of disease progression; in particular, the time to first episode of acute urinary retention or BPH-related surgery was significantly lower with combination therapy than tamsulosin treatment alone.
Filson, C. P., Hollingsworth, J. M., Clemens, J. Q. & Wei, J. T. The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J. Urol. 190, 2153–2160 (2013).
FDA. New medical device treats urinary symptoms related to enlarged prostates. FDA http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm368325.htm (2013).
Garcia, C., Chin, P., Rashid, P. & Woo, H. H. Prostatic urethral lift: a minimally invasive treatment for benign prostatic hyperplasia. Prostate Int. 3, 1–5 (2015).
Marra, G. et al. Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men’s ejaculatory function: time for a bespoke approach? Int. J. Urol. 23, 22–35 (2015).
Thomas, J. A. et al. A multicenter randomized noninferiority trial comparing GreenLight-XPS Laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH study. Eur. Urol. 69, 94–102 (2016).
De La Rosette, J. J. et al. Transurethral resection versus microwave thermotherapy of the prostate: a cost-consequences analysis. BJU Int. 92, 713–718 (2003).
Teng, J. et al. Photoselective vaporization with the green light laser versus transurethral resection of the prostate for treating benign prostate hyperplasia: a systematic review and meta-analysis. BJU Int. 111, 312–323 (2013).
Vincent, M. W. & Gilling, P. J. HoLEP has come of age. World J. Urol. 33, 487–493 (2015).
Yin, L., Teng, J., Huang, C. J., Zhang, X. & Xu, D. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J. Endourol. 27, 604–611 (2013).
O’Leary, M. P., Validity of the “bother score” in the evaluation and treatment of symptomatic benign prostatic hyperplasia. Rev. Urol. 7, 1–10 (2005).
Hong, S. J., Rayford, W., Valiquette, L. & Emberton, M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int. 95, 15–19 (2005).
Tubaro, A. & La Vecchia, C. The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey. Eur. Urol. 45, 767–772 (2004). This study concluded that patients with more-severe symptoms that affected activities of daily living ultimately had a lower QOL.
Mitropoulos, D. et al. Symptomatic benign prostate hyperplasia: impact on partners’ quality of life. Eur. Urol. 41, 240–244; discussion 244–245 (2002).
Sells, H., Donovan, J., Ewings, P. & MacDonagh, R. P. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int. 85, 440–445 (2000).
O’Leary, M. P. et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int. 92, 262–266 (2003).
Hunter, D. J., McKee, M., Black, N. A. & Sanderson, C. F. Health status and quality of life of British men with lower urinary tract symptoms: results from the SF-36. Urology 45, 962–971 (1995). In this study, 217 men ≥55 years of age with LUTS were surveyed; between 9% and 49% of those with moderate or severe urinary symptoms reported interference with some of their daily activities.
Derrett, S., Paul, C. & Morris, J. M. Waiting for elective surgery: effects on health-related quality of life. Int. J. Qual. Health Care 11, 47–57 (1999).
Thomas, K., Oades, G., Taylor-Hay, C. & Kirby, R. S. Acute urinary retention: what is the impact on patients' quality of life? BJU Int. 95, 72–76 (2005).
Faber, K. et al. Image-guided robot-assisted prostate ablation using water jet-hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J. Endourol. 29, 63–69 (2015).
Gilling, P., Reuther, R., Kahokehr, A. & Fraundorfer, M. Aquablation — image guided robotically-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int. http://dx.doi.org/10.1111/bju.13358 (2015).
Somani, B. K. et al. Prostate artery embolization (PAE) for benign prostatic hyperplasia (BPH). BJU Int. 114, 639–640 (2014).
Camara-Lopes, G. et al. The histology of prostate tissue following prostatic artery embolization for the treatment of benign prostatic hyperplasia. Int. Braz. J. Urol. 39, 222–227 (2013).
Pisco, J. M. et al. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur. Radiol. 23, 2561–2572 (2013).
McNeal, J. E. Regional morphology and pathology of the prostate. Am. J. Clin. Pathol. 49, 347–357 (1968).
McNeal, J. E. Origin and evolution of benign prostatic enlargement. Invest. Urol. 15, 340–345 (1978).
Roehrborn, C. G. Benign prostatic hyperplasia: an overview. Rev. Urol. 7, S3–S14 (2005).
Gravas, S. et al. Treatment of non-neurogenic male LUTS. Uroweb https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5 (2016).
As the clinical fellow in voiding dysfunction at Weill Cornell Medical College, J.C.F. is supported by ‘The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust’.
H.H.W. has received speaker's fees from Astellas and Janssen. All other authors declare no competing interests.
About this article
Cite this article
Chughtai, B., Forde, J., Thomas, D. et al. Benign prostatic hyperplasia. Nat Rev Dis Primers 2, 16031 (2016). https://doi.org/10.1038/nrdp.2016.31
Neferine improves oxidative stress and apoptosis in benign prostate hyperplasia via Nrf2-ARE pathway.
Redox Report (2021)
Abnormal expression of Rab27B in prostatic epithelial cells of benign prostatic hyperplasia alters intercellular communication
The International Journal of Biochemistry & Cell Biology (2021)
Ultrasound-guided transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a new minimally invasive interventional therapy
Acta Radiologica (2021)
Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia
World Journal of Urology (2021)